✦ LIBER ✦

Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy

✍ Scribed by M Castiglione-Gertsch; M Tattersall; A Hacking; A Goldhirsch; A Gudgeon; R.D Gelber; J Lindtner; A Coates; J Collins; M Isley; H.-J Senn; C.-M Rudenstam

Book ID: 117664098
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 99 KB
Volume: 33
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)10011-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Palliative chemotherapy with CMF after t

Palliative chemotherapy with CMF after the same adjuvant regimen for breast cancer

✍ M. Gerritsen; D.J.Th. Wagener; R.W.B. Schade; L.V.A.M. Beex 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 395 KB

O-3 Long-term results from the ZEBRA tri

O-3 Long-term results from the ZEBRA trial comparing Goserelin with CMF as adjuvant therapy in premenopausal women

✍ M. Kaufmann; W. Jonat; W. Sauerbrei; R. Blamey; M. Schumacher; for the Zoladex E 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 162 KB

PCN72 COST-EFFECTIVENESS OF LETROZOLE AN

PCN72 COST-EFFECTIVENESS OF LETROZOLE AND OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER USING UPDATED SURVIVAL DATA FROM THE BIG 1–98 AND ATAC TRIALS:A UK PERSPECTIVE

✍ J Karnon; S Kaura 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

Cost-effectiveness analysis of anastrozo

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB